Clinical Trials Logo

Malignant Brain Neoplasm clinical trials

View clinical trials related to Malignant Brain Neoplasm.

Filter by:

NCT ID: NCT04067960 Completed - Clinical trials for Malignant Solid Neoplasm

Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer

Start date: June 6, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.

NCT ID: NCT03649880 Recruiting - Clinical trials for Malignant Brain Neoplasm

Feasibility of FMISO in Brain Tumors

Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

NCT ID: NCT03510208 Recruiting - Malignant Glioma Clinical Trials

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Start date: May 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.